MAGEA3 and non-small cell lung carcinoma: An example is the combination therapy of MG1-MAGEA3 oncolytic virus with Ad-MAGEA3 vaccine and pembrolizumab targeting non-small cell lung cancer of patients who have undergone 1 course of standard cisplatin chemotherapy and at least one treatment with an antibody targeting programmed cell death 1 receptor (anti-PD-1, e.g., pembrolizumab) or (anti-PD-L1) (in 2017 in Canada—NCT02879760) [166].